The hip injection ladder and how far it goes

If a specialist has mentioned ChondroFiller as a possibility, the most useful starting point is understanding where it sits — and why it will not be right for every patient who walks through the door.

The hip injection ladder describes a private, sequential pathway of injectable options that sits entirely outside what the NHS commissions for hip patients. Above the corticosteroid injection that GPs can arrange, every step is self-funded. The rungs are roughly these:

• Corticosteroid — fast-acting anti-inflammatory relief, typically lasting 6–12 weeks; the most widely available starting point
• Hyaluronic acid (HA) — a viscosupplement that replaces depleted joint fluid to improve lubrication, lasting approximately 4–6 months
• PRP (platelet-rich plasma) — a biological stimulus drawn from the patient's own blood that may support the joint's repair processes over 6–12 months
• Arthrosamid (iPAAG) — a non-biodegradable hydrogel that integrates with the synovial lining to cushion the joint on a longer-term basis
• ChondroFiller — an injectable collagen scaffold that supports the body's own repair processes within a focal cartilage defect

This is a decision map, not a conveyor belt. The right rung depends on what the imaging shows — diffuse arthritis and a contained focal defect call for entirely different approaches. A patient with early generalised hip osteoarthritis and a patient with a discrete cartilage lesion after an injury may both be at the injection stage, but they are not candidates for the same treatment. The sections below explain which clinical picture each of the three main injectable rungs is designed for.

Hyaluronic acid — what viscosupplementation does in the hip joint

Hyaluronic acid has been used for hip injections since the early 2000s, with randomised controlled trials — including Qvistgaard et al. (2006) and Spitzer et al. (2010) using Hylan G-F 20 — establishing it as the first injectable step beyond corticosteroids. Its mechanism is straightforward: it restores the viscosity of depleted synovial fluid, improving lubrication across the joint surface. It does not repair cartilage; the distinction matters clinically, because patients with structural loss will not recover that tissue from a viscosupplement course.

Guideline bodies remain divided on how much that lubrication benefit translates to meaningful functional improvement in the hip specifically. OARSI offers conditional support; AAOS and ACR are more sceptical about hip-specific benefit. That uncertainty is reinforced by a 2025 updated meta-analysis of four RCTs involving 823 hip OA patients, which found that high-molecular-weight hyaluronic acid showed no statistically significant advantage over comparators — corticosteroids, PRP, or saline — on pain, WOMAC total, or physical function outcomes. Some patients do report relief lasting approximately 4–6 months, which can be useful for symptom management in mild-to-moderate hip OA, but the evidence does not support HA as a long-term structural solution.

When HA provides insufficient or short-lived benefit — or when imaging points to something beyond diffuse fluid loss — two further injectable options become relevant: Arthrosamid, which works by cushioning through synovial integration, and ChondroFiller, which targets focal defects through an entirely different, regenerative mechanism. Neither is a direct substitute for the other.

Arthrosamid in the hip — a hydrogel cushion with important caveats

Arthrosamid sits above HA on the ladder as a longer-acting option for patients whose hip OA is diffuse and poorly controlled rather than confined to a focal lesion. Its active component — a 2.5% cross-linked polyacrylamide hydrogel (iPAAG) comprising 97.5% water — integrates permanently with the synovial tissue lining the joint, providing a cushioning effect that reduces friction and may help modulate pain over an extended period.

Two caveats are worth stating plainly. First, UK regulatory approval covers knee osteoarthritis only; hip use is entirely off-label. There is no NHS funding pathway for Arthrosamid in the hip — or even in the knee. Second, no published hip-specific RCT data exists; evidence for hip use derives from off-label specialist experience rather than controlled trials equivalent to those available for the knee indication.

The mechanism is also distinct from anything further up the ladder. Arthrosamid does not recruit the patient's own repair cells, does not biodegrade, and does not rebuild cartilage structure. It is best understood as a durable hydrogel cushion — a meaningful property when diffuse OA is the clinical picture and surgery is not yet appropriate, but the wrong tool when imaging identifies a contained focal defect with structural tissue loss.

This is precisely why Arthrosamid and ChondroFiller should not be grouped together. They address different pathological pictures — generalised joint degeneration versus focal cartilage damage — and work through mechanisms that are not interchangeable.

ChondroFiller's rung — the regenerative scaffold for focal hip defects

Focal cartilage loss calls for a different tool altogether. ChondroFiller is a CE-marked Class III medical device — manufactured by Meidrix Biomedicals GmbH in Germany — consisting of acellular murine-derived Type I collagen that, once injected into the hip joint, gels in situ within 3–5 minutes to form a temporary three-dimensional scaffold.

The mechanism is described clinically as acellular matrix-induced chondrogenesis: rather than delivering living cells, the scaffold provides a structural and chemotactic template that encourages the patient's own progenitor cells — from the synovium and subchondral bone — to migrate into the defect and begin an endogenous repair process. To put the three rungs in plain parallel terms: HA lubricates, Arthrosamid cushions permanently, and ChondroFiller promotes the body's own repair within a focal area.

Patient selection here is precise, and the evidence makes clear what it rules out. ChondroFiller is indicated for focal, contained Grade III/IV cartilage defects of up to approximately 6 cm² with healthy surrounding cartilage borders. It is not a treatment for diffuse, end-stage hip osteoarthritis. That distinction is supported directly by published hip data: in the Mazek et al. prospective cohort (Journal of Hip Preservation Surgery, 2021), patients with pre-existing Tönnis grade 2–3 OA had poor results, while 17 of 21 patients with focal acetabular lesions achieved good or excellent outcomes at 3–5-year follow-up.

In the current service pathway, ChondroFiller is delivered as an ultrasound-guided outpatient injectable scaffold — not a surgical or arthroscopic procedure. Image guidance is essential given the hip's depth and proximity to major vessels; the scaffold is placed directly over the focal defect at an outpatient appointment under local anaesthesia.

What the hip-specific evidence shows

Responders in the Mazek et al. cohort (Journal of Hip Preservation Surgery, 2021) gained approximately 30 points on the modified Harris Hip Score — a change that exceeds the threshold clinicians typically regard as meaningful for hip outcomes. One piece of context matters when reading that figure: Mazek studied ChondroFiller placed during hip arthroscopy, not delivered as an outpatient ultrasound-guided injection. The 17-of-21 good/excellent rate at 3–5 years applies to arthroscopic application in 26 adults with femoroacetabular impingement (FAI) and acetabular defects exceeding 2 cm²; injection-route evidence for the hip currently rests on off-label clinical experience rather than a dedicated prospective trial. That does not diminish the patient-selection lessons the cohort establishes, but it is the honest starting point for any discussion of the data.

The most clinically important of those lessons concerns who does poorly. Patients with Tönnis grade 2–3 osteoarthritis had poor outcomes in the Mazek cohort. This is not a caveat buried in the small print — it is the data-driven rationale for the selection criteria used in specialist assessment today, and the reason imaging is central to determining whether a patient is a genuine candidate.

Accurate placement is a separate but equally non-negotiable requirement. A 2016 systematic review by Hoeber et al. found that landmark-guided hip injections achieved correct intra-articular placement in approximately 72% of attempts (95% CI 56–85%), against 100% under image guidance (p<0.0001). For a scaffold that must rest precisely over a contained focal defect, ultrasound guidance is not an optional upgrade — it is a clinical minimum.

A 2024 biomechanical study adds one practical rehabilitation note: the collagen gel is initially unstable under full joint loading, which means protected weight-bearing is required while the scaffold stabilises. Any treating specialist will factor this into the post-procedure plan from the outset.

Accessing ChondroFiller for the hip in the UK

For hip patients in the UK, the practical reality is straightforward: there is no NHS pathway for ChondroFiller in the hip joint. The commissioned NHS hip pathway moves directly from conservative management to total hip replacement; cartilage-matrix commissioning currently covers the knee only. Anyone pursuing ChondroFiller for a hip cartilage defect is doing so as a self-funded private patient.

Guide costs at UK specialist clinics range from approximately £3,000 to £8,000, with the figure varying by centre and the volume of product needed — any confirmed pricing should come directly from the treating clinic before a decision is made.

Before cost is relevant, however, imaging is. Assessment typically requires recent MRI or CT arthrogram to confirm that the defect is focal, contained, and of a grade and size consistent with the indication. That step matters because, as the evidence makes clear, not every hip patient presenting with cartilage pain will be a ChondroFiller candidate — Arthrosamid, PRP, or a surgical referral may be the more appropriate recommendation.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment, with clinics in Sleaford and Grantham — a practical option for patients across Lincolnshire and the wider non-London catchment who want specialist input without travelling to London.

The outcome of that assessment is not a foregone conclusion. Its purpose is to establish where the patient sits on the injection ladder — and whether ChondroFiller, or a different pathway entirely, is the clinically appropriate next step.

1. [1] Viscosupplementation with High Molecular Weight Hyaluronic Acid for Hip Osteoarthritis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2025). https://doi.org/10.1055/s-0046-1819579 https://doi.org/10.1055/s-0046-1819579
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
3. [3] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
4. [4] Controlled, randomized multicenter study comparing ChondroFiller liquid with microfracturing for focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1